Open access · US-GOV via ClinicalTrials.gov Clinical trial

A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Phase III Clinical Trial to Evaluate Efficacy, Safety and Immunogenicity of Recombinant Zoster Vaccine (CHO Cell) in Adults Aged 40 Years and Above

Authors not listed

MAXVAX Biotechnology Limited Liability Company · 2024

Dysbiosis Human Randomized controlled trial

Abstract

The purpose of the sutdy is to evaluate efficacy, safety and immunogenicity of Recombinant Zoster Vaccine (CHO Cell) with 2 doses at 2-month interval in adults aged 40 years and older.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source: ClinicalTrials.gov
Canonical: link ↗
Fetched: 2026-11-01 MST

Cite this

APA

Anonymous. (2024). A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Phase III Clinical Trial to Evaluate Efficacy, Safety and Immunogenicity of Recombinant Zoster Vaccine (CHO Cell) in Adults Aged 40 Years and Above. <em>MAXVAX Biotechnology Limited Liability Company</em>. https://clinicaltrials.gov/study/NCT06447779

Vancouver

Anonymous. A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Phase III Clinical Trial to Evaluate Efficacy, Safety and Immunogenicity of Recombinant Zoster Vaccine (CHO Cell) in Adults Aged 40 Years and Above. MAXVAX Biotechnology Limited Liability Company. 2024.

BibTeX

@misc{anon2024AMulti, title = {A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Phase III Clinical Trial to Evaluate Efficacy, Safety and Immunogenicity of Recombinant Zoster Vaccine (CHO Cell) in Adults Aged 40 Years and Above}, author = {Anonymous}, journal = {MAXVAX Biotechnology Limited Liability Company}, year = {2024}, }